{"entity":{"id":"helena-earl","kind":"person","name":"Helena Earl","aka":[],"tldr":"Led PERSEPHONE, which showed six months of trastuzumab is nearly as good as twelve for most patients.","summary":"Helena Earl was chief investigator of PERSEPHONE, the 4,000-patient UK trial showing six months of adjuvant trastuzumab is non-inferior to twelve months with less cardiotoxicity, and of the neoadjuvant ARTemis and Neo-tAnGo trials. Her work anchors the de-escalation debate in HER2-positive early breast cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Earl%20HM%5BAuthor%5D%20PERSEPHONE"}],"tags":["breast","de-escalation","her2"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["trastuzumab"],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":["persephone"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Clinical Cancer Medicine, University of Cambridge","institutionId":"cruk-cambridge-centre","specialisms":["HER2-positive breast cancer","Treatment de-escalation","Neoadjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Earl%20HM%5BAuthor%5D%20PERSEPHONE"}],"papers":[{"title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(19)30650-6"},{"title":"Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis)","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)00086-8"}],"orcid":"0000-0003-1549-8094"},"route":"/people/helena-earl/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/"}],"trial":[{"id":"persephone","kind":"trial","name":"PERSEPHONE","route":"/trials/persephone/"}]}}